Future Prospects of Global Laboratory Proficiency Testing Market

Image
Laboratory Proficiency Testing Market  The global Laboratory Proficiency Testing Market is estimated to be valued at US$ 1.29 billion in 2023 and is expected to exhibit a CAGR of 7.3% over the forecast period 2023 - 2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Laboratory proficiency testing involves evaluating the performance of laboratories for a given scope of testing through inter-laboratory comparisons. It helps assess the quality and competence of laboratories by determining reproducibility and accuracy of test results. Proficiency testing products are used by laboratories to determine method validity and accuracy, and improve testing processes. Market Key Trends: One of the major trends in the laboratory proficiency testing market is the growing number of accredited medical laboratories. Accreditation assures compliance with ISO 15189 and ISO/IEC 17025 standards, which require participation in proficiency testing programs. Acc...

Hodgkin’s Lymphoma Treatment Market Drivers and Regional Analysis

Lymphoma is a malignancy that affects the body's lymphocytes, or white blood cells. There are two forms of lymphoma: Hodgkin's and Non- Hodgkin's. Classic Hodgkin's Lymphoma and nodular lymphocyte dominated Hodgkin's Lymphoma are the two types of Hodgkin's Lymphoma. Fever, abrupt weight loss, and swollen lymph nodes are some of the symptoms that indicate the presence of Hodgkin's Lymphoma in the body. Chemotherapy alone or in conjunction with radiotherapy is the most common treatment for Hodgkin's Lymphoma.

Global Hodgkin’s Lymphoma Treatment Market Drivers

The global Hodgkin's lymphoma market is predicted to develop as regulatory agencies approve medications for the treatment of Hodgkin's lymphoma. In 2018, Health Canada approved Seattle Genetics, Inc.'s supplementary New Drug Submission, which increases the use of Adcetris (brentuximab vedotin) in combination with AVD (adriamycin, vinblastine, and dacarbazine) chemotherapy in patients with previously untreated Stage IV Hodgkin lymphoma (HL). Adcetris is used in conjunction with doxorubicin, vinblastine, and dacarbazine to treat adult patients with previously untreated Stage III or IV classical Hodgkin lymphoma (cHL).

 

Hodgkin’s Lymphoma Treatment Market
Hodgkin,s Lymphoma Treatment Market

Global Hodgkin’s Lymphoma Treatment Market Regional Analysis

Over the projection period, North America is expected to maintain its dominance in the worldwide Hodgkin's lymphoma market. The expansion of the North American Hodgkin's lymphoma therapy market is predicted to be fueled by frequent research and development activities conducted by the government and other organisations. For example, in December 2016, the Ohio State University Comprehensive Cancer Center and the National Cancer Institute (NCI) started a U.S. FDA clinical trial of Ibrutinib in conjunction with Nivolumab in patients with classical Hodgkin's Lymphoma in the United States to see how effective it is. Ibritunib may inhibit cancer cell growth by inhibiting growth-related enzymes, but Nivolumab may inhibit cancer cell growth by targeting distinct cells.

Comments

Popular posts from this blog

Future Prospects of Global Laboratory Proficiency Testing Market

Survival Suits Market Size, Share, Outlook, and Opportunity Analysis, 2023-2030

Global Ophthalmoscopes Market Overview and Impact of Coronavirus (Covid-19) Pandemic